Structure Therapeutics reports Q2 net loss $23.3M; completes Phase 2a enrollment for GSBR-1290

Structure Therapeutics Inc.

2023-Q2 EPS reported -$0.44

Net loss of $23.3M for Q2 2023 vs $15.5M for Q2 2022; includes $1.7M stock-based compensation.
Cash, equivalents and short-term investments of $224.6M at June 30, 2023; expected to fund operations through at least 2025.
R&D expenses $19.4M for Q2 2023 vs $10.2M in Q2 2022, driven by GLP-1R franchise advancement.
Completed enrollment in 12-week Phase 2a study of oral GLP-1 agonist GSBR-1290 (94 participants); topline data expected latter half Q4 2023.
Appointed Ted W. Love, M.D. to Board of Directors; preparations underway for global Phase 2b study in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Structure Therapeutics Inc. reported the second quarter ended June 30, 2023 results: net income Net loss totaled $23.3 million.

Period: the second quarter ended June 30, 2023
Net income: Net loss totaled $23.3 million
Result: reported results

Exact text from the filing

Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089815

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.